» Articles » PMID: 36581490

Inflammation-Controlled Anti-Inflammatory Hydrogels

Overview
Journal Adv Sci (Weinh)
Date 2022 Dec 29
PMID 36581490
Authors
Affiliations
Soon will be listed here.
Abstract

While autoregulative adaptation is a common feature of living tissues, only a few feedback-controlled adaptive biomaterials are available so far. This paper herein reports a new polymer hydrogel platform designed to release anti-inflammatory molecules in response to the inflammatory activation of human blood. In this system, anti-inflammatory peptide drugs, targeting either the complement cascade, a complement receptor, or cyclophilin A, are conjugated to the hydrogel by a peptide sequence that is cleaved by elastase released from activated granulocytes. As a proof of concept, the adaptive drug delivery from the gel triggered by activated granulocytes and the effect of the released drug on the respective inflammatory pathways are demonstrated. Adjusting the gel functionalization degree is shown to allow for tuning the drug release profiles to effective doses within a micromolar range. Feedback-controlled delivery of covalently conjugated drugs from a hydrogel matrix is concluded to provide valuable safety features suitable to equip medical devices with highly active anti-inflammatory agents without suppressing the general immunosurveillance.

Citing Articles

Design Strategies and Application Potential of Multifunctional Hydrogels for Promoting Angiogenesis.

Wang M, Chen J, Luo Y, Feng M, Yang Q, Tang Y Int J Nanomedicine. 2024; 19:12719-12742.

PMID: 39624117 PMC: 11609418. DOI: 10.2147/IJN.S495971.


Cutting-Edge Hydrogel Technologies in Tissue Engineering and Biosensing: An Updated Review.

Parvin N, Kumar V, Joo S, Mandal T Materials (Basel). 2024; 17(19).

PMID: 39410363 PMC: 11477805. DOI: 10.3390/ma17194792.


Sprayable anti-adhesive hydrogel for peritoneal macrophage scavenging in post-surgical applications.

Song W, Lee C, Jeong H, Kim S, Hwang N Nat Commun. 2024; 15(1):8364.

PMID: 39333108 PMC: 11436759. DOI: 10.1038/s41467-024-52753-0.


Biomimetic Anticoagulated Porous Particles with Self-Reporting Structural Colors.

Chen H, Bian F, Luo Z, Zhao Y Adv Sci (Weinh). 2024; 11(22):e2400189.

PMID: 38520728 PMC: 11165554. DOI: 10.1002/advs.202400189.


Inflammation-Controlled Anti-Inflammatory Hydrogels.

Helmecke T, Hahn D, Matzke N, Ferdinand L, Franke L, Kuhn S Adv Sci (Weinh). 2022; 10(7):e2206412.

PMID: 36581490 PMC: 9982591. DOI: 10.1002/advs.202206412.

References
1.
Mastaglio S, Ruggeri A, Risitano A, Angelillo P, Yancopoulou D, Mastellos D . The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020; 215:108450. PMC: 7189192. DOI: 10.1016/j.clim.2020.108450. View

2.
Langhorst J, Boone J, Lauche R, Rueffer A, Dobos G . Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial. J Crohns Colitis. 2016; 10(7):786-94. DOI: 10.1093/ecco-jcc/jjw044. View

3.
Woodruff T, Nandakumar K, Tedesco F . Inhibiting the C5-C5a receptor axis. Mol Immunol. 2011; 48(14):1631-42. DOI: 10.1016/j.molimm.2011.04.014. View

4.
Li J, Vlodavsky I . Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost. 2009; 102(5):823-8. DOI: 10.1160/TH09-02-0091. View

5.
Catz S, McLeish K . Therapeutic targeting of neutrophil exocytosis. J Leukoc Biol. 2020; 107(3):393-408. PMC: 7044074. DOI: 10.1002/JLB.3RI0120-645R. View